CA1277883C - Dosage form for delivering acid sensitive beneficial agent - Google Patents
Dosage form for delivering acid sensitive beneficial agentInfo
- Publication number
- CA1277883C CA1277883C CA000544092A CA544092A CA1277883C CA 1277883 C CA1277883 C CA 1277883C CA 000544092 A CA000544092 A CA 000544092A CA 544092 A CA544092 A CA 544092A CA 1277883 C CA1277883 C CA 1277883C
- Authority
- CA
- Canada
- Prior art keywords
- wall
- dosage form
- beneficial agent
- environment
- fluid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Abstract
ABSTRACT
A dosage form is disclosed, which dosage form comprises an inside wall comprising means for changing its structural integrity in response to the pH environment inside the dosage form.
A dosage form is disclosed, which dosage form comprises an inside wall comprising means for changing its structural integrity in response to the pH environment inside the dosage form.
Description
~Z~3 DELIVERING ACID SENSITIVE
6 This invention pertains to both a novel and unique dosage 7 form. The dosage form comprises an inner wall, an outer wall and a 8 compartment comprising a beneficial agent that exhibits in solution a g pH less than 7. In operation the beneficial agent is continuously 1o delivered from the dosage form and at the end of the delivery period 11 alkaline solution present in the environment of use enters the dosage 12 form changes and alters the structural integrity of the inner wall, 13 whereupon the dosage form collapses thereby facilitating discharge of 14 the dosage form from the environment of use.
18 Since the beginnlng of antiquity, both pharmacy and medicine 19- have sought a dosage form for the controlled administration of a beneficial drug. The first written reference to a dosage from is in 21 the Eber Papyrus written about 1552 ~.C. The Eber Papyrus mentioned 22 dosage forms such as anal suppositories, vaginal pessaries, ointments, 23 oral pill formulations and other dosage preparations. About 2500 24 years passed without any advance in dosage form development until the Arab physician Rhazes, 863-925 A.D., invented the coated pill. About 26 a century later the Persian Avicenna, 980-1037 A.D., coated pills with 27 gold or silver for increasing patient acceptability and for enhancing 28 the effectiveness of the drug. Also, around this time, the first ~Z~7883 1 tablet was described in Arabian manuscripts written by Al-Zahrawi, 2 936-1009 A.D. The manuscripts described a tablet formed from the 3 hollow impressions in two matched-facing tablet molds. Pharmacy and 4 medicine waited about 800 years for the next innovation in dosage forms when in 1833 Mothes invented the soft gelatin capsule for 6 administering a drug. Fifteen years later, in 1848 Murdock invented 7 the two-piece hard gelatin capsule. Th coating of pills with tolu was 8 first recommended about 1860, and in 1884 Unna introduced enteric g coating with Keratin ~oated pills.
The technical value of sustained released dosage forms was 11 recognized by Lipowski who, in 1938, discussed the desirability of a 12 slow and constant supply of a drug to an organism. Lipowski's patents 13 were the first to describe an oral dosage for consisting of a number 14 of small drug containing beads, having different thickness of coating, utilized to give a slow and constant release of drug on ingestion. In 16 195Z Blythe conceived of the use of multiple small pellets which could 17 be coated and which, independent of pH, would have reproducible 18 release rates and prolonged drug release. Blythe uses varying coating 19 thicknesses of time-delay materials in a single capsule.
The next quantum and profound advancement in dosage forms 21 came in 1972 with the invention of the osmotic delivery system by 22 inventors Theeuwes and Higuchi. This unique osmotic dosage form is 23 manufactured in one embodiment for oral use, and in this embodiment it 24 em6races the appearance of a tablet with at least one delivery portal.
The delivery portal can be preformed or formed by leaching a pore 26 former during operation of the dosage form. It is the first oral 27 dosage form that delivers throughout the entire gastrointestinal tract 28 a known amount of drug per unit time at a controlled rate of delivery.
iZ77883 1 The oral osmotic device maintains its physical and chemical integrity 2 during the prolonged period of time it transits the total length of 3 the gastrointestinal tract.
4 The above discussed osmotic dosage form represents an outstanding and pioneering advancement in the art and science of drug 6 delivery. Now it has been discovered a need exists for a delivery 7 system that loses its physical and chemical integrity at the end of 8 the delivery period for discharging the dosage form from the 9 environment of use, mainly the gastrointestinal tract. The need exists for a dosage form that loses its structural integrity, that is 11 for a dosage form that becomes compressible and/or self-destructs for 12 avoiding possible retention of the empty dosage form within the 13 gastrointestinal tract.
AS~ECT G THE INVENTION
Accordingly, in view of the above presentations, it is an 16 immediate ~spect of this invention to provide a novel and useful 17 dosage form that satisfies that critical need associated with the 18 prior art.
19 Another aspe~t of the invention is to provide a novel dosage 2 form that delivers substantialiy all of its beneficial agent from the dosage from followed by the dosage form collapsing for easy passage 22 from the gastrointestinal tract.
23 Another aspect of the present invention is to provide a 24 dosage form manufactured as an osmotic device shaped, sized, structured and adapted for the controlled and continuous delivery of a 26 beneficial drug throughout the gastrointestinal tract followed by the 27 device losing its structural integrity at the end of the delivery 2)3 period for facilitating easy exit from the tract.
~277883 1 Another aspect of the present invention is to provide a 2 controlled time release dosage form comprising an inner wall that 3 breaks down at the end of the delivery period for enhancing the 4 peristaltic expulsion of the dosage form from the environment of use.
Another aspect of the present invention is to provide a 6 dosage that delivers a drug constantly for sustained blood levels in 7 the body dS a result of controlled and sustained release of drug in 8 the gastrointestinal tract, comprising the stomach and the intestines, 9 and which dosage form under the influence of the alkaline environment of the intestine alters and changes its structure for enhancing its 11 peristaltic expulsion from the intestine.
12 Another aspect of the present invention is to provide an 13 oral, osmotic dosage form for delivering essentially all of its drug 14 at a controlled rate in the stomach and in the intestines, with the dosage form keeping its physical and chemical integrity during the 16 drug dispensing in the stomach and intestine and then losing its 17 physical and chemical integrity after the dispensing period in the 18 - intestine, and which dosage form is relatively economical in cost to l9 manufacture, provides the physician with d dependable dosage form, and is well-adapted for practlcal and acceptable patient use.
21 Another asPect of the present invention is to provide an 22 oral, osmotic device that dispenses drug at a rate controlled by the 23 device in the stomach and in the intestine and then in response to the 24 biological environment of the intestine adopts a structure that is readily discharged from the animal body.
26 Other aspect , features and advantages of this invention 27 will be more apparent to those versed in the dispensing art from the 28 following detailed specification, taken in conjunction with the 12~7883 drawings and the accompanying claims.
The present invention therefore provides a dosage form for dispensing a beneficial agent formulation to an environment of use, the dosage form comprising:
(a) a first wall that permits the passage of fluid and comprises means for keeping its chemical integrity in a first fluid environment exhibiting a pH less than 5 and for losing its chemical integrity in a second fluid environment exhibiting a pH greater than 5;
(b) a second wall that permits the passage of fluid and comprises means for keeping its chemical integrity in a first fluid environment exhibiting a pH less than 5 and for keeping its chemical integrity in a second environment exhibiting a pH
greater than 5;
(c) a compartment formed by the first wall and the second wall with the first wall surrounding and facing the inside of the compartment and the second wall surrounding the first wall and facing the environment of use;
(d) a beneficial agent formulation in the compartment, which agent formulation forms with fluid that enters the compart-ment a fluid environment exhibiting a pH less than 5; and, (e) at least one passageway through the walls for dispensing the beneficial agent formulation from the dosage form to the environment of use over time; and (f) wherein fluid from the environment exhibiting a pH
greater than 5 entersthe dosage form causing the first wall at the ~ ~ 67696-109 end of the dispensing of the beneficial agent to lose its chemical integrity for facilitating discharge of the dosage form from the environment of use.
A further embodiment of the invention comprises a dos-age form for dispensing a beneficial agent formulation to a biological environment of use, the dosage form comprising:
(a) a first wall that permits the passage of fluid and comprises means for keeping its chemical integrity in a first fluid environment inside the dosage form exhibiting a pH less than 5 and for losing its chemical integrity in a second fluid environment inside the dosage form exhibiting a pH greater than 5;
(b) a second wall that permits the passage of fluid and comprises means for keeping its chemical integrity in a first fluid environment exhibiting a pH less than 5 and for keeping its chemical integrity in a second environment exhibiting a pH greater than 5;
(c) a compartment formed by the first wall and by the second wall which first wall surrounds and faces the inside of the compartment and which second wall surrounds the first wall and faces the biological environment of use;
(d) a beneficial agent formulation in the compartment, which agent formulation forms with fluid ~hat enters the compart-ment a fluid environment exhibiting a pH less than 5/ and a hydro-philic hydrogel formulation in the compartment that aids in dispensing the agent formulation from the dosage form;
(e) at least one passageway through the walls connecting - 5a -~883 67696-109 the compartment with the biological environment of use for dis-pensing the beneficial agent formulation from the dosage form over a prolonged period of time; and (f) wherein fluid from the environment having a pH
greater than 5 enters the dosage form through the passageway causing the first wall at the end of the dispensing of the beneficial agent to lose its chemical integrity for facilitating discharge of the dosage form from the environment of use.
BRIEF DESCRIPTION OF THE DRAWINGS
In the drawing figures, which are not drawn to scale - 5b -~7883 but are set forth to illustrate various embodiments of the present invention, the drawing figures are as follows:
Figure 1 is a general view of a dosage form manufac-tured as an osmotic device for dispensing a beneficial agent throughout the gastrointestinal tract;
Figure 2 is a view of the dosage form of Figure 1 seen in opened view for illustrating the internal structure of the dosage form; and, Figure 3 is a view of another embodiment of the dosage form of Figure 1 seen in opened section for illustrating a dif-ferent internal structure of the dosage form;
Figure 4 is a view of another embodiment of the dosage form of Figure 1 seen in opened section for illustrating a dif-ferent releasing means of the dosage form.
In the drawing figures, and in the specification, like parts in related figures are identified by like numbers. The terms appearing earlier in the specification, and in the descrip-tion of the drawing figures, as well as embodiments thereof, are further described elsewhere in the disclosure.
DETAILED DESCRIPTION OF THE
DRAWING FIGURES
Turning now to the drawing figures in detail, which drawing figures are an example of the dosage form provided by this invention, and which examples are not to be construed as limiting the invention, - 5c -~Z77883 1 one example of the dosage form is illustrated in Figure 1 and 2 designated by the numeral 20. In Figure 1, dosage form 20 comprises 3 a body member 21 comprising a wall 22 that surrounds and forms an 4 internal compartment not seen in Figure 1. Dosage form 20 further comprises at least one exit means 23 for connecting the interior of 6 dosage form 20 with the exterior environment of use.
7 Figure 2 illustrates dosage form 20 of Figure 1 comprising 8 body 21, wall 22, and exit means 23. Wall 22 comprises an outer wall 9 24 and an inner wall 25. Wall 22 comprising outside wall 24 and inside wall 25 surrounds and defines an interior compartment 26.
11 Composite wall 22, comprising outside wall 24 and inside wall 25 at 12 least in part, or totally, comprises a composition that is permeable 13 to the passage of an exterior fluid present in the environment of use.
14 O~utside wall 24 comprises a polymeric composition that is inert and maintains its physical and chemical integrity during the dispensing 16 life time of dosage form 20. The phrase "physical and chemical 17 integrity" denotes outside wall 24 does not lose its structure and it 18 does not change during the dispensing life of dosage form 20. Typical 19 materials for forming outside wall 24 comprises selectively semipermeable polymers known as osmosis and as reverse osmosis 21 polymers. These polymeric compositions comprise a cellulose ester, 22 cellulose ether, cellulose ester-ether, cellulose acylate, cellulose 23 diacylate, cellu10se triacylate, cellulose acetate, cellulose 24 diacetate, and cellulose triacetate. Other semipermeable polymeric compositions include cellulose acetate ethyl carbamate, cellulose 26 acetate methyl carbamate, cellulose acetate ethyl carbamate, cellulose 27 acetate succinate, cellulose acetate dimethyl-aminoacetate, cellulose 28 acetate ethylcarbamate, cellulose acetate chloracetate, cellulose ~Z'77883 1 dipalmdte, cellulose dioctanoate, cellulose acetate valerate, 2 cellulose acetate succinate, cellulose propionate succinate, and the 3 like. In d presently preferred embodiment outside wa11 24 comprises a 4 thickness of from 0.01 mm to 3 mm. Semipermeable polymers are known to the dispensing art in U.S. Patent Nos. 3,845,770; 3,916,899;
6 4,160,020 and 4,250,108.
7 Inside wall 25 comprises a polymeric formulation that is 8 sensitive to changes in pH. Wall 25 keeps its physical and chemical 9 integrity in the presence of beneficial acidic agents that form an acidic solution having a pH less than 4 with fluid that enters dosage 11 form 20. Inside wall 25 maintains its integrity throughout the 12 dispensing of the beneficial agent from dosage form 20. Inside wall 13 25, in a preferred embodiment, loses its integrity when a solution 14 having a pH greater than 5 present in the environment of use enters the dosage form and causes inside wall 25 to lose its integrity. The 16 loss of integrity of inside wall 25 is accompanied by a collapse of 17 outside wall 24 thereby increasing its discharge from the environment -18 of use. Representative materials for forming inside wall 25 are 19 materials that dissolve or disintegrate on exposure to the alkaline - -solution or the alkaline environment inside dosage form 20. The 21 solution also includes the intestinal buffer solution of the 22 gastrointestinal tract. The materials for forming inside wall 25 23 include ionizable polyacids, frequently a long-chain polymer with 24 ionizable carboxyl groups and the like. Materials for forming inside wall 25 include keratin, keratin over sandarac-tolu, B-naphthyl 26 benzoate and acetotanin, balsam of Peru, balsam of tolu, shellac, gum 27 resin and salol~shellac formalized gelatin, myristic acid-hydrogenated 28 castor oil, shellac n-butyl stearate, cellulose carboxylic acid .
i2~883 1 phthalate, cellulose ethyl phthalate, cellulose acetate phthalate, 2 starch acetate phthalate, amylose acetate phthalate, hydroxypropyl 3 methylcellulose phthalate, hydroxypropyl ethylcellulose phthalate, 4 cellulose acetate hexahydrophthalate, hydroxypropyl methylcellulose hexahydrophthatate, polyacylic acid, polyacylic acid co-esters, and 6 the like. Inside wall 25 is preferably from 1 mm to 5 mm thick. ~n 7 in vitro test for determining the disintegration rate and time of a 8 material in an alkaline environment is reported in Pharmaceutical 9 Technology, by Chambliss, Sept. 19&3. Materials sensitive to pH are reported in Remlngton's Pharmaceutical Sciences, 14th Ed., pp 604 to 11 605, 1965; and in Biopharmaceutics and Relevant Pharmacokinetics, 12 1st Ed., pp 158 to 165, 1971.
13 Internal compartment 26 comprises a beneficial agent 27, 1~ that is in a presently preferred embodiment a beneficial drug. The drug that can be housed in compartment 26 includes any physiologically 16 or pharmacologically active drug that produces a local or a systemic 17 effect in animals. The term animals includes warm-blooded mammals, 18 humans, primates, household, sport, farm and zoo animals. The active 19 drugs that can be delivered include lnorganic and organic drugs with- -out limitations, drugs that can act on the central nervous system, 21 depressants, hypnotics, sedatives, psychic energizers, tranquilizers, 22 anticonvulsants, muscle relaxants, antiparkinson, anti-inflammatories, 23 local anesthetics, mùscle contractants, antimicrobials, antimalarials, 24 hormonal agents, contraceptives, diuretics, sympathomimetics, anti-parasitics, neoplastics, hypoglycemics, ophthalmics, diagnostics, 26 cardiovascular drugs and the like. The beneficial drugs useful for 27 the purpose of the present invention comprises drugs, or a drug and an 28 acidic osmagent, or a drug and an acidic buffer, that exhibit an ~.z~7883 1 acidic pH in solution. The beneficial drugs are in a presently 2 preferred embodiment the acid addition drugs. Examples of non-toxic, 3 pharmaceutically acceptable acid addition salts are hydrochloric, 4 hydrobromic, sulfuric, phosphoric, acetic, propionic, citric, oxalic, maleic, and the like. More specific examples of acid drugs that 6 exhibit a pH of less than 4 comprise a member selected from the group 7 consisting of cyclizine hydrochloride, thiethylperazine maleate, 8 diphenoxyleate hydrobromide, phentolamine mesylate, cyclopentolate 9 hydrochloride, mepenzolate bromide, cyclomethycaine sulfate, tripelennamine citrate, trimeprazine tartrate, and the like. The 11 beneficial drugs are known to the art in Pharmaceutical Sciences, by 12 Remington, 14th Ed., 1979 published by Mack Publishing Co., Easton, 13 Pa.; The Drug, The Nurse, The_Patient, Including current Drug 14 Handbook, 1974-76, by Falconer et al., published by Saunders Co., Philadelphia, Pa.; and Physician's Desk Reference, 40th Ed., 1986, 16 published by Medical Economics Co., Oradell, NJ.
17 The term "pH" as used herein denotes the ph valuesof an 18 aqueous solution as a number describing its acidity or alkalinity.
19 The pH values are determined by acid-base titrations, and by using electronic pH meters as reported in the Encyclopedia Of Chemistry, 2nd 21 Ed., pages 799 to 800, 1966, published by Van Nostrand-Reinhold Co., 22 New York, NY. The effects of an acidic solution, or a alkaline 23 solution on the integrity of a pH sensitive materials in direct 24 contact with the solution is ascertainable by the procedures described in J. Amer. Pharm. Assoc. Vol. 27, pp 379 to 384, 1938; and The 26 Pharmacopeia Of The United States Of America, 18th Ed., pp 932 to 934, 27 1970.
28 Figure 3 is an opened view of another dispensing dosage form ~2~778a3 1 20 provided by this invention. In Figure 3, dosage form 20 comprises 2 body 21, and dual wall 22. Dual wall 22 comprises outside wall 24 3 that permits the passage of fluid into dosage form 20 and inside wall 4 25 formed of an alkaline-sensitive material. Inside wall 25 loses its integrity after the dispensing of drug from dosage form 20 and in the 6 presence of biological alkaline fluid from the intestine and the colon 7 that enters dosage form 20 after the dispensing of the drug. Dual 8 wall 22 surrounds interior compartment 26 comprising at least one exit 9 means 23.
Internal compartment 26 of Figure 3, in a presently 11 preferred embodi~ent, houses a first layer 27 comprising a beneficial 12 drug identified by dots, and an expandable layer 28, identified by 13 dashes. Drug formulation 27 was described above Figure 2. Expandable 14 layer 28 comprises a hydrophilic, hydrogel formulation that exhibits fluid absorbing and/or imbibing properties. The hydrophilic materials 16 forming layer 28 comprises a hydrophilic polymeric formulation that 17 can interact with water and aqueous biological fluids and swell or 18 expand to an equilibrium state. In operation, first layer 27 and 19 second layer 28 cooperate to deliver drug formulation from dosage 20, with second layer absorbant fluid expanding and exerting pressure 21 against first layer 27. First layer 27 optionally absorbs fluid and 22 forms a dispensable formulation and by the combined operations second 23 layer 28 expands against first layer 27 and urge it from compartment 24 ?6. In this manner, drug formulation is delivered through exit means 23 to the environment of use.
26 The hydrophilic hydrogel composition comprising layer 28 27 swells or expands to a very high degree, usually exhibiting from a 28 nonhydrated state, a 2 to 50 fold increase in volume. Representative -~277883 1 hydrophil1ic hydrogels consists of d member selected from the group 2 consisting of poly(hydroxyalkyl methacrylate) having d molecular 3 weight of 15,000 to 5,000,000; poly(vinylpyrrolidone) having a 4 molecular weight of about 10,000 to 360,000; poly(vinyl alcohol) having a low acetate content and lightly cross-linked with glyoxal, 6 formaldehyde or glutaraldehyde and having a degree of polymerization 7 of from 200 to 30,000; poly(ethylene oxide) having a molecular weight 8 from 10,000 to 6,000,000; the sodium salt of carboxymethylcellulose 9 having a molecular weight from 10,000 to 2,000,000; acidic carboxy polymer known as carboxypolymethylene and carboxyvinyl polymers 11 consisting of acrylic acid lightly cross-linked with polyallyl sucrose 12 and sold under the trademark Carbopol~, acidic carboxypolymer having a 13 molecular weight of 200,000 to 6,000,000, including sodium acidic 14 carboxyvinyl hydrogel and potassium acidic carboxyvinyl hydrogel;
Cyanamer~ polyacrylamide; and the like. The representative polymers 16 are known in the Handbook Of Common Polymers, by Scott and Roff, 17 published by the Chemical Company, Cleveland, OH.; ACS Symposium 18 Series, No. 31, by Ratner and Hoffman, pp 1 to 36, 1976, published by -19 the American Chemical Society; and ln Recent Advances In Drug Delivery 20 Systems, by 5chacht, pp 259 to 278, publ-ished by Plenum Press, NY.
21 Figure 4 depicts in opened section another delivery dosage 22 form 20 provided by the invention. Dosage form 20 in Figure 4 23 comprises body member 21, wall 22 comprising outside wall 24-and 24 inside 25, compartment 26 comprising drug formulation 27 and exit means 23. The expression exit means as used herein comprises means 26 and methods suitable for releasing drug formulation 27 from 27 compartment 26.- The expression "at least one passageway" includes 28 aperture, orifice, bore, pore, porous element through which drug can ~277883 1 migrate, a hollow fiber, capillary tube and the like. The expression 2 includes also a material that erodes, or is leached from wall 22 in 3 the fluid environment of use to produce at least one passageway in the 4 dosage form. Representative materials suitable for forming at least one passageway, or a multiplicity of passageways include an erodible 6 poly(lactic) or poly(glycolic) acid member in the wall, a gelatinous 7 filament, leachable materials such a fluid removable pore forming 8 polysaccharides, salts, oxides or salt alcohols, and the like. A
g passageway or plurality of passageways can be formed through the outside and inside walls by leaching a material such as sorbitol from 11 the walls to produce a controlled release passageway. Dosage form 20 12 can be constructed with one or more passageways in spaced dpart 13 relation on more than one surface of a dosage form. The passageway 14 can be a microporous member inserted into the wall, with the microporous member preformed or formed during operation of the dosage 16 form. Passageways and equipment for forming passageways are disclosed 17 in U.S. Patent Nos. 3,916,899; 4,063,064 and 4,088,864. Passageways 18 Df controlled dimensions in an osmotic system formed by leaching a 19- pore former such as sorbitol are discl-osed in U.S. Patent No. - - --20 4,200,098. ~ -Zl The amount of drug present in the dosage form generally is 22 an amount sufficient for performing a therapeutic program. Generally, 23 the dispensing dosage form will contain from 0.05 ng to 1500 mg, or 24 more with individual dosage forms containing, for example, 25 ng, 1 mg, 25 mg, 50 mg, 125 mg, 250 mg, 750 mg, and the like. The dosage 26 form can be administered once, twice daily, or like, over a prolonged 27 period of one day to one year, or longer. The phrase drug formulation 28 as used for the purpose of this invention denotes the drug is present - 12~7883 1 in the compartment nedt, or with tablet forming excipients.
2 Wall 22, comprising outside wall 24 and inside wall 25, 3 surrounding drug formulation 27, or surrounding drug formulation 27 4 and expandable member 28, in the various embodiments can be formed using an air suspension procedure. The procedure consists in 6 suspending and tumbling the compartment forming members and wall 7 forming compositions in a current of air and using the wall forming 8 composition until the inside wall, and then the outside wall is 9 applied to the compartment forming members. The air suspension procedure is well-suited for independently forming each wdll in 11 separate operations. The air suspension procedure is described in 12 U.S. Patent No. 2,799,240; in J. Am. Pharm. Assoc., Vol. 48, pp 451 13 to 459, 1959; and ibid, Vol. 49, pp 82 to 84, 1960. The wall-forming 14 composition can be applied with a Wurster~ air suspension coater, or an Aeromatic~ air suspension coater. Other wall-forming techniques 16 such as pan coating can be used for providing the dosage form. In 17 the pan coating system, the wall forming compositions are deposited 18 by successive spraying of the composition accompanied by tumbling in -1g a rotating pan. A pan coater is used to produce a thicker wall. - -Finally, the wali coated dosage form is-dried in a forced air oven at 21 50 C for a week, or in a temperature and humidity controlled oven, at Z2 50 C and 50 C R.H. for 24 hours.
23 Exemplary solvents for manufacturing a wall include inert 24 organic and inorganic solvents that do not adversely harm the wall, and the final dosage form. The solvents broadly include a member 26 selected from the group consisting of an alcohol, ketone, ester, 27 ether, aliphatic, halogenated, cycloaliphatic, aromatic, heterocyclic, 28 aqueous solvents, and the like.
lZq'7883 1 The compartment forming members comprising a drug and other 2 ingredients are manufactured in one process by blending a powdered 3 drug and other core forming ingredients in a fluid bed granulator.
4 After the powdered ingredients are dry blended in the granulator, a granulating fluid, for example, polyvinyl pyrrolidone in water, is 6 sprayed onto the powdered member. The coated powder is dried in the 7 granulator. After drying a lubricant such as magnesium stearate is 8 added to the granulator. The granules are then pressed and wall 9 coated with a wall forming composition.
The dosage form of the invention can be manufactured by 11 other manufacturing techniques. For example, in one manufacture the 12 beneficial drug and other compartment core forming materials are 13 blended and pressed into a solid layer. The layer possesses 14 dimensions that corresponds to the internal dimensions of the area occupied in the dosage form. Optionally, the drug formulation can be 16 blended with a solvent, mixed by conventional methods such as 17 ballmilling, callendering, stirring, or rollmilling and then pressed 18 into a preselected shape. The compressed compartment forming mass 19 then is coated with an inner and outer wall. The wall forming composition can be applied by press coating, molding, spraying, 21 dipping or air suspension procedures. The air suspension and air 22 tumbling procedures comprise suspending and tumbling the pressed 23 composition untll surrounded with the respective walls. Dosage forms 24 comprising a drug formulation layer in contacting arrangement, and then coated with the inner and outer walls.
26 In another manufacture, the dosage form is made by the wet 27 granulation technique. In the wet granulation technique, the drug is 28 blended with other compartment forming ingredients using an organic ~2~7883 1 cosolvent, such as isopropyl alcohol-methylene dichloride, 80/20 v/v 2 (volume/volume) ~s the granulation fluid. The ingredients are passed 3 through a 40 mesh screen and blended in a mixer. Then, the blend is 4 dried for 18 to 24 hours at 42 C in a forced an oven. Next, a lubricant is added to the dry blend, and the newly formed mixture put 6 into milling jars and mixed on a jar mill for 5 to 15 minutes. The 7 composition is pressed into d layer in a Manesty~ layer press at a 8 maximum load of 2 tons. The pressed mass is fed to a Kilian~ dry cota g press and coated with an exterior wall.
DESCRIPTION OF EXAMPLES
- OF THE INVENTION
12 The following examples are merely illustrative of the 13 present invention and they should not be considered as limiting the 14 scope of the invention in anyway, as these examples and other equivalents thereof will become more apparent to those versed in the 16 dispensing art in the light of the present disclosure, the drawing 17 figures and the accompanying claims.
1g A dosage form is manufactured for delivering a beneficial drug as follows: first, a compartment-forming composition is prepared 21 by dissolving 4 9 of polyvinyl pyrrolidone in 30 ml of a cosolvent 22 consisting of 95% ethanol and 5% distilled water, and then blending 23 the moist polyvinyl pyrrolidone with a composition comprising 475 9 of 24 cimetidine hydrochloride and 10 9 of cross-linked sodium carboxymethyl cellulose previously passed through a 40 mesh stainless steel sieve to 26 yield a homogeneous blend. Next, an additional 70 ml of the cosolvent 27 consisting of ethanol and distilled water is added to the cimetidine 28 hydrochloric acid blend to form a wet granulation. The wet lZ77883 1 granulation is passed through a 10 mesh stainless steel sieve and then 2 dried at 50C for 18 to 20 hours. Then 5 9 of magnesium stearate is 3 added to the dried granulation which is passed through a 20 mesh 4 stainless steel sieve. The final blend is compressed into a number of S cores of drug having an average core weight of 742.2 mg and a hardness 6 of 12-18 kp.
7 The individual cores were coated with an inside wall-forming 8 composition comprising 30% hydroxypropylmethylcellulose phthalate, 15%
9 cellulose acetate having an acetyl content of 39.8%, 45~ sorbitol and 10% polyethylene glycol. The wall-forming coating solution consists 11 of 80/20 (v/v) acetone/water blend. The total solid content is 3%, 12 with mixing conducted with a Cole-Parmer~ stirrer. The wall forming 13 composition is coated around the cores in an air suspension machine.
14 The first applied inside wall is about 4 mils thick. Next, an outside wall about 0.5 mil thick comprising cellulose acetate having an acetyl 16 content of 32% is applied in contacting arrangement over the first 17 formed inside wall. The second form outside semipermeable wall is 18 applied using a cosolvent comprising methylene chloride/methanol, 1g 80/20, (v/v) wit~ a total solid content of 2%. The wall forming semipermeable composition is mixed with a Cole-Parmer~ mixer and 21 applied with an Aeromatic~ air suspension coater. The final dosage 22 form has a pair of spaced apart passageways of 0.38 mm diameter. The 23 dosage forms, after dispensing its drug in a distilled water 24 environment is transferred to an artificial intestinal fluid environment. In the artificial intestinal fluid, the inside wall 26 undergoes dissolution in the fluid, as the inside wall dissolves due 27 to hydroxide io~s from the artificial intestinal fluid entering the 28 dosage form, thereby causing the dosage form to collapse.
12~78a3 2 The procedure described in Example 1 is repeated with all 3 condition as previously set forth, except that in this example the 4 outside semipermeable wall consists of cellulose acetate having an acetyl content of 36~D, or cellulose acetate having an acetyl content 6 of 39.8%. The initial collapse pressure of the cellulose acetate 36%
7 wall, and the cellulose acetate 39.8% outside wall overcoated around 8 the inside wall of Example 1 is 150 mm Hg, and 150 mm Hg respectively.
g The walls exhibited a collapse pressure of 60 mm Hg, are 60 mm Hg when exposed to artificial intestinal fluid, indicating the interior wall 11 dissolves and weakens as to lose its structural-integrity and 12 continuity in the structural integrity and continuity in the presence 13 of artificial intestinal fluid exhibiting a pH greater than 4. The 14 dissolution of the wall in intestinal fluid enhances the easy of expulsion of the dosage form through the anorectal route from the 16 gastrointestinal tract.
18 A dosage form for dispensing a beneficia~ drug having an -19 acidic function is manufactured as follows: first, 600 9 of indomethacin, 2220 g-of potyethyl~ene oxide having a molecular weight 21 of 200,000 and 150 g of hydroxypropyl methyl cellulose are blended and 22 screened 40 mesh screen and then added to a mixing bowl, and dry mixed 23 for 15 to 20 minutes. Next, 2000 ml of anhydrous, denatured ethanol 24 is slowly added and mixing continued for 15 to 20 minutes more. Then, the wet mass is passed through a 16 mesh screen, spread on a white 26 paper overnight and air dried at room temperature. Next, the dry mass 27 is passed through a 16-mesh screen and 30 9 of magnesium stearate 28 added and blended therewith for 5 minutes, to yield ~he drug lZ~7883 1 containing core-forming composition.
2 Next, 4480 g of polyethylene oxide having a molecular weight 3 of about 5,000,000 is screened through a 40 mesh screen. Then, 2030 9 4 of sodium chloride, and 350 9 of hydroxypropyl methylcellulose and mixed for 15 to 20 minutes. Next, a granulating solvent consisting of 6 6 1 of ethanol absolute and 100 ml of methanol is slowly added to the 7 blending ingredients and the wet granulation mixed for 5 to 10 8 minutes. The wet granulation is removed from the mixer and then 9 passed through a 16 mesh screen onto pap-er-lined oven trays. The trays are placed into an oven at 30-35C and allowed to dry for 24 11 hours. After drying the dry granulation is passed through a 16-mesh 12 stainless steel screen and 30 9 of magnesium stearate added thereto.
13 Then, all the ingredients are blended for 15 minutes to provide a 14 uniform, homogeneous hydrophilic, hydrogel composition.
Next, a number of drug cores weighing 60 mg are pressed into 16 a layer and then placed into contacting arrangement with a 240 mg 17 1ayer of the hydrophilic, hydrogel composition~ The first and second 18 layers are surrounded with a wall forming composition 22.5% hydroxy--lg propylmethylcellulose phthalate, 25% hydroxypropylmethylcellulose, 25 polyethylene glycol, 22.5% cellulose acetate having an acetyl content 21 of 39.8% and 5% of adipic acld. The wall is applied from a cosolvent 22 comprising methylene chloride/methanol, 80/20 (v/v) with a total solid 23 content of 4%. The wall forming ingredients were mixed with a Cole-24 Parmer~ stirrer and applied with an Aeromatic~ air suspension coater.
Then, a semipermeable wall is coated around the inside wall.
26 The outside wall cellu7Ose acetate having an acetyl content of 39.8%.
27 The semipermeable wall is applied with a cosolvent comprising 28 methylene chloride/methanol, 90/10, (v/v), with a solid content of 2%
~2~7883 1 The wall forming ingredients are mixed with a Cole-Parmer~ stirrer, 2 and coated with an Aeromatic~ air suspension coater. The dosage form 3 had a 0.38 mm orifice, and after dispensing its drug layer, the inside 4 wall in artificial intestinal fluid exhibits fissuring and collapses for reducing the possible accumulation of dosage forms in the 6 gastrointestinal tract.
8 The above procedure of Example 3 is repeated with all the 9 conditions as set forth, except that in this example the outside wall comprises ethyl cellulose.
11 In summary, it will be readily appreciated that the present 12 invention contributes to the art an unobvious dosage form manufactured 13 as a drug delivery device possessing wide and practical application.
14 While the invention has been described and pointed out in detail and with reference to operative embodiments thereof, it will be understood 16 that those skilled in the art will appreciate that various changes, 17 modifications, substitutions and omissions can be made without 18 departing from the spirit of the invention. It is-intended, there-19 fore, ~hat the invention embrace those equivalents within the scope of the claims which follow.
18 Since the beginnlng of antiquity, both pharmacy and medicine 19- have sought a dosage form for the controlled administration of a beneficial drug. The first written reference to a dosage from is in 21 the Eber Papyrus written about 1552 ~.C. The Eber Papyrus mentioned 22 dosage forms such as anal suppositories, vaginal pessaries, ointments, 23 oral pill formulations and other dosage preparations. About 2500 24 years passed without any advance in dosage form development until the Arab physician Rhazes, 863-925 A.D., invented the coated pill. About 26 a century later the Persian Avicenna, 980-1037 A.D., coated pills with 27 gold or silver for increasing patient acceptability and for enhancing 28 the effectiveness of the drug. Also, around this time, the first ~Z~7883 1 tablet was described in Arabian manuscripts written by Al-Zahrawi, 2 936-1009 A.D. The manuscripts described a tablet formed from the 3 hollow impressions in two matched-facing tablet molds. Pharmacy and 4 medicine waited about 800 years for the next innovation in dosage forms when in 1833 Mothes invented the soft gelatin capsule for 6 administering a drug. Fifteen years later, in 1848 Murdock invented 7 the two-piece hard gelatin capsule. Th coating of pills with tolu was 8 first recommended about 1860, and in 1884 Unna introduced enteric g coating with Keratin ~oated pills.
The technical value of sustained released dosage forms was 11 recognized by Lipowski who, in 1938, discussed the desirability of a 12 slow and constant supply of a drug to an organism. Lipowski's patents 13 were the first to describe an oral dosage for consisting of a number 14 of small drug containing beads, having different thickness of coating, utilized to give a slow and constant release of drug on ingestion. In 16 195Z Blythe conceived of the use of multiple small pellets which could 17 be coated and which, independent of pH, would have reproducible 18 release rates and prolonged drug release. Blythe uses varying coating 19 thicknesses of time-delay materials in a single capsule.
The next quantum and profound advancement in dosage forms 21 came in 1972 with the invention of the osmotic delivery system by 22 inventors Theeuwes and Higuchi. This unique osmotic dosage form is 23 manufactured in one embodiment for oral use, and in this embodiment it 24 em6races the appearance of a tablet with at least one delivery portal.
The delivery portal can be preformed or formed by leaching a pore 26 former during operation of the dosage form. It is the first oral 27 dosage form that delivers throughout the entire gastrointestinal tract 28 a known amount of drug per unit time at a controlled rate of delivery.
iZ77883 1 The oral osmotic device maintains its physical and chemical integrity 2 during the prolonged period of time it transits the total length of 3 the gastrointestinal tract.
4 The above discussed osmotic dosage form represents an outstanding and pioneering advancement in the art and science of drug 6 delivery. Now it has been discovered a need exists for a delivery 7 system that loses its physical and chemical integrity at the end of 8 the delivery period for discharging the dosage form from the 9 environment of use, mainly the gastrointestinal tract. The need exists for a dosage form that loses its structural integrity, that is 11 for a dosage form that becomes compressible and/or self-destructs for 12 avoiding possible retention of the empty dosage form within the 13 gastrointestinal tract.
AS~ECT G THE INVENTION
Accordingly, in view of the above presentations, it is an 16 immediate ~spect of this invention to provide a novel and useful 17 dosage form that satisfies that critical need associated with the 18 prior art.
19 Another aspe~t of the invention is to provide a novel dosage 2 form that delivers substantialiy all of its beneficial agent from the dosage from followed by the dosage form collapsing for easy passage 22 from the gastrointestinal tract.
23 Another aspect of the present invention is to provide a 24 dosage form manufactured as an osmotic device shaped, sized, structured and adapted for the controlled and continuous delivery of a 26 beneficial drug throughout the gastrointestinal tract followed by the 27 device losing its structural integrity at the end of the delivery 2)3 period for facilitating easy exit from the tract.
~277883 1 Another aspect of the present invention is to provide a 2 controlled time release dosage form comprising an inner wall that 3 breaks down at the end of the delivery period for enhancing the 4 peristaltic expulsion of the dosage form from the environment of use.
Another aspect of the present invention is to provide a 6 dosage that delivers a drug constantly for sustained blood levels in 7 the body dS a result of controlled and sustained release of drug in 8 the gastrointestinal tract, comprising the stomach and the intestines, 9 and which dosage form under the influence of the alkaline environment of the intestine alters and changes its structure for enhancing its 11 peristaltic expulsion from the intestine.
12 Another aspect of the present invention is to provide an 13 oral, osmotic dosage form for delivering essentially all of its drug 14 at a controlled rate in the stomach and in the intestines, with the dosage form keeping its physical and chemical integrity during the 16 drug dispensing in the stomach and intestine and then losing its 17 physical and chemical integrity after the dispensing period in the 18 - intestine, and which dosage form is relatively economical in cost to l9 manufacture, provides the physician with d dependable dosage form, and is well-adapted for practlcal and acceptable patient use.
21 Another asPect of the present invention is to provide an 22 oral, osmotic device that dispenses drug at a rate controlled by the 23 device in the stomach and in the intestine and then in response to the 24 biological environment of the intestine adopts a structure that is readily discharged from the animal body.
26 Other aspect , features and advantages of this invention 27 will be more apparent to those versed in the dispensing art from the 28 following detailed specification, taken in conjunction with the 12~7883 drawings and the accompanying claims.
The present invention therefore provides a dosage form for dispensing a beneficial agent formulation to an environment of use, the dosage form comprising:
(a) a first wall that permits the passage of fluid and comprises means for keeping its chemical integrity in a first fluid environment exhibiting a pH less than 5 and for losing its chemical integrity in a second fluid environment exhibiting a pH greater than 5;
(b) a second wall that permits the passage of fluid and comprises means for keeping its chemical integrity in a first fluid environment exhibiting a pH less than 5 and for keeping its chemical integrity in a second environment exhibiting a pH
greater than 5;
(c) a compartment formed by the first wall and the second wall with the first wall surrounding and facing the inside of the compartment and the second wall surrounding the first wall and facing the environment of use;
(d) a beneficial agent formulation in the compartment, which agent formulation forms with fluid that enters the compart-ment a fluid environment exhibiting a pH less than 5; and, (e) at least one passageway through the walls for dispensing the beneficial agent formulation from the dosage form to the environment of use over time; and (f) wherein fluid from the environment exhibiting a pH
greater than 5 entersthe dosage form causing the first wall at the ~ ~ 67696-109 end of the dispensing of the beneficial agent to lose its chemical integrity for facilitating discharge of the dosage form from the environment of use.
A further embodiment of the invention comprises a dos-age form for dispensing a beneficial agent formulation to a biological environment of use, the dosage form comprising:
(a) a first wall that permits the passage of fluid and comprises means for keeping its chemical integrity in a first fluid environment inside the dosage form exhibiting a pH less than 5 and for losing its chemical integrity in a second fluid environment inside the dosage form exhibiting a pH greater than 5;
(b) a second wall that permits the passage of fluid and comprises means for keeping its chemical integrity in a first fluid environment exhibiting a pH less than 5 and for keeping its chemical integrity in a second environment exhibiting a pH greater than 5;
(c) a compartment formed by the first wall and by the second wall which first wall surrounds and faces the inside of the compartment and which second wall surrounds the first wall and faces the biological environment of use;
(d) a beneficial agent formulation in the compartment, which agent formulation forms with fluid ~hat enters the compart-ment a fluid environment exhibiting a pH less than 5/ and a hydro-philic hydrogel formulation in the compartment that aids in dispensing the agent formulation from the dosage form;
(e) at least one passageway through the walls connecting - 5a -~883 67696-109 the compartment with the biological environment of use for dis-pensing the beneficial agent formulation from the dosage form over a prolonged period of time; and (f) wherein fluid from the environment having a pH
greater than 5 enters the dosage form through the passageway causing the first wall at the end of the dispensing of the beneficial agent to lose its chemical integrity for facilitating discharge of the dosage form from the environment of use.
BRIEF DESCRIPTION OF THE DRAWINGS
In the drawing figures, which are not drawn to scale - 5b -~7883 but are set forth to illustrate various embodiments of the present invention, the drawing figures are as follows:
Figure 1 is a general view of a dosage form manufac-tured as an osmotic device for dispensing a beneficial agent throughout the gastrointestinal tract;
Figure 2 is a view of the dosage form of Figure 1 seen in opened view for illustrating the internal structure of the dosage form; and, Figure 3 is a view of another embodiment of the dosage form of Figure 1 seen in opened section for illustrating a dif-ferent internal structure of the dosage form;
Figure 4 is a view of another embodiment of the dosage form of Figure 1 seen in opened section for illustrating a dif-ferent releasing means of the dosage form.
In the drawing figures, and in the specification, like parts in related figures are identified by like numbers. The terms appearing earlier in the specification, and in the descrip-tion of the drawing figures, as well as embodiments thereof, are further described elsewhere in the disclosure.
DETAILED DESCRIPTION OF THE
DRAWING FIGURES
Turning now to the drawing figures in detail, which drawing figures are an example of the dosage form provided by this invention, and which examples are not to be construed as limiting the invention, - 5c -~Z77883 1 one example of the dosage form is illustrated in Figure 1 and 2 designated by the numeral 20. In Figure 1, dosage form 20 comprises 3 a body member 21 comprising a wall 22 that surrounds and forms an 4 internal compartment not seen in Figure 1. Dosage form 20 further comprises at least one exit means 23 for connecting the interior of 6 dosage form 20 with the exterior environment of use.
7 Figure 2 illustrates dosage form 20 of Figure 1 comprising 8 body 21, wall 22, and exit means 23. Wall 22 comprises an outer wall 9 24 and an inner wall 25. Wall 22 comprising outside wall 24 and inside wall 25 surrounds and defines an interior compartment 26.
11 Composite wall 22, comprising outside wall 24 and inside wall 25 at 12 least in part, or totally, comprises a composition that is permeable 13 to the passage of an exterior fluid present in the environment of use.
14 O~utside wall 24 comprises a polymeric composition that is inert and maintains its physical and chemical integrity during the dispensing 16 life time of dosage form 20. The phrase "physical and chemical 17 integrity" denotes outside wall 24 does not lose its structure and it 18 does not change during the dispensing life of dosage form 20. Typical 19 materials for forming outside wall 24 comprises selectively semipermeable polymers known as osmosis and as reverse osmosis 21 polymers. These polymeric compositions comprise a cellulose ester, 22 cellulose ether, cellulose ester-ether, cellulose acylate, cellulose 23 diacylate, cellu10se triacylate, cellulose acetate, cellulose 24 diacetate, and cellulose triacetate. Other semipermeable polymeric compositions include cellulose acetate ethyl carbamate, cellulose 26 acetate methyl carbamate, cellulose acetate ethyl carbamate, cellulose 27 acetate succinate, cellulose acetate dimethyl-aminoacetate, cellulose 28 acetate ethylcarbamate, cellulose acetate chloracetate, cellulose ~Z'77883 1 dipalmdte, cellulose dioctanoate, cellulose acetate valerate, 2 cellulose acetate succinate, cellulose propionate succinate, and the 3 like. In d presently preferred embodiment outside wa11 24 comprises a 4 thickness of from 0.01 mm to 3 mm. Semipermeable polymers are known to the dispensing art in U.S. Patent Nos. 3,845,770; 3,916,899;
6 4,160,020 and 4,250,108.
7 Inside wall 25 comprises a polymeric formulation that is 8 sensitive to changes in pH. Wall 25 keeps its physical and chemical 9 integrity in the presence of beneficial acidic agents that form an acidic solution having a pH less than 4 with fluid that enters dosage 11 form 20. Inside wall 25 maintains its integrity throughout the 12 dispensing of the beneficial agent from dosage form 20. Inside wall 13 25, in a preferred embodiment, loses its integrity when a solution 14 having a pH greater than 5 present in the environment of use enters the dosage form and causes inside wall 25 to lose its integrity. The 16 loss of integrity of inside wall 25 is accompanied by a collapse of 17 outside wall 24 thereby increasing its discharge from the environment -18 of use. Representative materials for forming inside wall 25 are 19 materials that dissolve or disintegrate on exposure to the alkaline - -solution or the alkaline environment inside dosage form 20. The 21 solution also includes the intestinal buffer solution of the 22 gastrointestinal tract. The materials for forming inside wall 25 23 include ionizable polyacids, frequently a long-chain polymer with 24 ionizable carboxyl groups and the like. Materials for forming inside wall 25 include keratin, keratin over sandarac-tolu, B-naphthyl 26 benzoate and acetotanin, balsam of Peru, balsam of tolu, shellac, gum 27 resin and salol~shellac formalized gelatin, myristic acid-hydrogenated 28 castor oil, shellac n-butyl stearate, cellulose carboxylic acid .
i2~883 1 phthalate, cellulose ethyl phthalate, cellulose acetate phthalate, 2 starch acetate phthalate, amylose acetate phthalate, hydroxypropyl 3 methylcellulose phthalate, hydroxypropyl ethylcellulose phthalate, 4 cellulose acetate hexahydrophthalate, hydroxypropyl methylcellulose hexahydrophthatate, polyacylic acid, polyacylic acid co-esters, and 6 the like. Inside wall 25 is preferably from 1 mm to 5 mm thick. ~n 7 in vitro test for determining the disintegration rate and time of a 8 material in an alkaline environment is reported in Pharmaceutical 9 Technology, by Chambliss, Sept. 19&3. Materials sensitive to pH are reported in Remlngton's Pharmaceutical Sciences, 14th Ed., pp 604 to 11 605, 1965; and in Biopharmaceutics and Relevant Pharmacokinetics, 12 1st Ed., pp 158 to 165, 1971.
13 Internal compartment 26 comprises a beneficial agent 27, 1~ that is in a presently preferred embodiment a beneficial drug. The drug that can be housed in compartment 26 includes any physiologically 16 or pharmacologically active drug that produces a local or a systemic 17 effect in animals. The term animals includes warm-blooded mammals, 18 humans, primates, household, sport, farm and zoo animals. The active 19 drugs that can be delivered include lnorganic and organic drugs with- -out limitations, drugs that can act on the central nervous system, 21 depressants, hypnotics, sedatives, psychic energizers, tranquilizers, 22 anticonvulsants, muscle relaxants, antiparkinson, anti-inflammatories, 23 local anesthetics, mùscle contractants, antimicrobials, antimalarials, 24 hormonal agents, contraceptives, diuretics, sympathomimetics, anti-parasitics, neoplastics, hypoglycemics, ophthalmics, diagnostics, 26 cardiovascular drugs and the like. The beneficial drugs useful for 27 the purpose of the present invention comprises drugs, or a drug and an 28 acidic osmagent, or a drug and an acidic buffer, that exhibit an ~.z~7883 1 acidic pH in solution. The beneficial drugs are in a presently 2 preferred embodiment the acid addition drugs. Examples of non-toxic, 3 pharmaceutically acceptable acid addition salts are hydrochloric, 4 hydrobromic, sulfuric, phosphoric, acetic, propionic, citric, oxalic, maleic, and the like. More specific examples of acid drugs that 6 exhibit a pH of less than 4 comprise a member selected from the group 7 consisting of cyclizine hydrochloride, thiethylperazine maleate, 8 diphenoxyleate hydrobromide, phentolamine mesylate, cyclopentolate 9 hydrochloride, mepenzolate bromide, cyclomethycaine sulfate, tripelennamine citrate, trimeprazine tartrate, and the like. The 11 beneficial drugs are known to the art in Pharmaceutical Sciences, by 12 Remington, 14th Ed., 1979 published by Mack Publishing Co., Easton, 13 Pa.; The Drug, The Nurse, The_Patient, Including current Drug 14 Handbook, 1974-76, by Falconer et al., published by Saunders Co., Philadelphia, Pa.; and Physician's Desk Reference, 40th Ed., 1986, 16 published by Medical Economics Co., Oradell, NJ.
17 The term "pH" as used herein denotes the ph valuesof an 18 aqueous solution as a number describing its acidity or alkalinity.
19 The pH values are determined by acid-base titrations, and by using electronic pH meters as reported in the Encyclopedia Of Chemistry, 2nd 21 Ed., pages 799 to 800, 1966, published by Van Nostrand-Reinhold Co., 22 New York, NY. The effects of an acidic solution, or a alkaline 23 solution on the integrity of a pH sensitive materials in direct 24 contact with the solution is ascertainable by the procedures described in J. Amer. Pharm. Assoc. Vol. 27, pp 379 to 384, 1938; and The 26 Pharmacopeia Of The United States Of America, 18th Ed., pp 932 to 934, 27 1970.
28 Figure 3 is an opened view of another dispensing dosage form ~2~778a3 1 20 provided by this invention. In Figure 3, dosage form 20 comprises 2 body 21, and dual wall 22. Dual wall 22 comprises outside wall 24 3 that permits the passage of fluid into dosage form 20 and inside wall 4 25 formed of an alkaline-sensitive material. Inside wall 25 loses its integrity after the dispensing of drug from dosage form 20 and in the 6 presence of biological alkaline fluid from the intestine and the colon 7 that enters dosage form 20 after the dispensing of the drug. Dual 8 wall 22 surrounds interior compartment 26 comprising at least one exit 9 means 23.
Internal compartment 26 of Figure 3, in a presently 11 preferred embodi~ent, houses a first layer 27 comprising a beneficial 12 drug identified by dots, and an expandable layer 28, identified by 13 dashes. Drug formulation 27 was described above Figure 2. Expandable 14 layer 28 comprises a hydrophilic, hydrogel formulation that exhibits fluid absorbing and/or imbibing properties. The hydrophilic materials 16 forming layer 28 comprises a hydrophilic polymeric formulation that 17 can interact with water and aqueous biological fluids and swell or 18 expand to an equilibrium state. In operation, first layer 27 and 19 second layer 28 cooperate to deliver drug formulation from dosage 20, with second layer absorbant fluid expanding and exerting pressure 21 against first layer 27. First layer 27 optionally absorbs fluid and 22 forms a dispensable formulation and by the combined operations second 23 layer 28 expands against first layer 27 and urge it from compartment 24 ?6. In this manner, drug formulation is delivered through exit means 23 to the environment of use.
26 The hydrophilic hydrogel composition comprising layer 28 27 swells or expands to a very high degree, usually exhibiting from a 28 nonhydrated state, a 2 to 50 fold increase in volume. Representative -~277883 1 hydrophil1ic hydrogels consists of d member selected from the group 2 consisting of poly(hydroxyalkyl methacrylate) having d molecular 3 weight of 15,000 to 5,000,000; poly(vinylpyrrolidone) having a 4 molecular weight of about 10,000 to 360,000; poly(vinyl alcohol) having a low acetate content and lightly cross-linked with glyoxal, 6 formaldehyde or glutaraldehyde and having a degree of polymerization 7 of from 200 to 30,000; poly(ethylene oxide) having a molecular weight 8 from 10,000 to 6,000,000; the sodium salt of carboxymethylcellulose 9 having a molecular weight from 10,000 to 2,000,000; acidic carboxy polymer known as carboxypolymethylene and carboxyvinyl polymers 11 consisting of acrylic acid lightly cross-linked with polyallyl sucrose 12 and sold under the trademark Carbopol~, acidic carboxypolymer having a 13 molecular weight of 200,000 to 6,000,000, including sodium acidic 14 carboxyvinyl hydrogel and potassium acidic carboxyvinyl hydrogel;
Cyanamer~ polyacrylamide; and the like. The representative polymers 16 are known in the Handbook Of Common Polymers, by Scott and Roff, 17 published by the Chemical Company, Cleveland, OH.; ACS Symposium 18 Series, No. 31, by Ratner and Hoffman, pp 1 to 36, 1976, published by -19 the American Chemical Society; and ln Recent Advances In Drug Delivery 20 Systems, by 5chacht, pp 259 to 278, publ-ished by Plenum Press, NY.
21 Figure 4 depicts in opened section another delivery dosage 22 form 20 provided by the invention. Dosage form 20 in Figure 4 23 comprises body member 21, wall 22 comprising outside wall 24-and 24 inside 25, compartment 26 comprising drug formulation 27 and exit means 23. The expression exit means as used herein comprises means 26 and methods suitable for releasing drug formulation 27 from 27 compartment 26.- The expression "at least one passageway" includes 28 aperture, orifice, bore, pore, porous element through which drug can ~277883 1 migrate, a hollow fiber, capillary tube and the like. The expression 2 includes also a material that erodes, or is leached from wall 22 in 3 the fluid environment of use to produce at least one passageway in the 4 dosage form. Representative materials suitable for forming at least one passageway, or a multiplicity of passageways include an erodible 6 poly(lactic) or poly(glycolic) acid member in the wall, a gelatinous 7 filament, leachable materials such a fluid removable pore forming 8 polysaccharides, salts, oxides or salt alcohols, and the like. A
g passageway or plurality of passageways can be formed through the outside and inside walls by leaching a material such as sorbitol from 11 the walls to produce a controlled release passageway. Dosage form 20 12 can be constructed with one or more passageways in spaced dpart 13 relation on more than one surface of a dosage form. The passageway 14 can be a microporous member inserted into the wall, with the microporous member preformed or formed during operation of the dosage 16 form. Passageways and equipment for forming passageways are disclosed 17 in U.S. Patent Nos. 3,916,899; 4,063,064 and 4,088,864. Passageways 18 Df controlled dimensions in an osmotic system formed by leaching a 19- pore former such as sorbitol are discl-osed in U.S. Patent No. - - --20 4,200,098. ~ -Zl The amount of drug present in the dosage form generally is 22 an amount sufficient for performing a therapeutic program. Generally, 23 the dispensing dosage form will contain from 0.05 ng to 1500 mg, or 24 more with individual dosage forms containing, for example, 25 ng, 1 mg, 25 mg, 50 mg, 125 mg, 250 mg, 750 mg, and the like. The dosage 26 form can be administered once, twice daily, or like, over a prolonged 27 period of one day to one year, or longer. The phrase drug formulation 28 as used for the purpose of this invention denotes the drug is present - 12~7883 1 in the compartment nedt, or with tablet forming excipients.
2 Wall 22, comprising outside wall 24 and inside wall 25, 3 surrounding drug formulation 27, or surrounding drug formulation 27 4 and expandable member 28, in the various embodiments can be formed using an air suspension procedure. The procedure consists in 6 suspending and tumbling the compartment forming members and wall 7 forming compositions in a current of air and using the wall forming 8 composition until the inside wall, and then the outside wall is 9 applied to the compartment forming members. The air suspension procedure is well-suited for independently forming each wdll in 11 separate operations. The air suspension procedure is described in 12 U.S. Patent No. 2,799,240; in J. Am. Pharm. Assoc., Vol. 48, pp 451 13 to 459, 1959; and ibid, Vol. 49, pp 82 to 84, 1960. The wall-forming 14 composition can be applied with a Wurster~ air suspension coater, or an Aeromatic~ air suspension coater. Other wall-forming techniques 16 such as pan coating can be used for providing the dosage form. In 17 the pan coating system, the wall forming compositions are deposited 18 by successive spraying of the composition accompanied by tumbling in -1g a rotating pan. A pan coater is used to produce a thicker wall. - -Finally, the wali coated dosage form is-dried in a forced air oven at 21 50 C for a week, or in a temperature and humidity controlled oven, at Z2 50 C and 50 C R.H. for 24 hours.
23 Exemplary solvents for manufacturing a wall include inert 24 organic and inorganic solvents that do not adversely harm the wall, and the final dosage form. The solvents broadly include a member 26 selected from the group consisting of an alcohol, ketone, ester, 27 ether, aliphatic, halogenated, cycloaliphatic, aromatic, heterocyclic, 28 aqueous solvents, and the like.
lZq'7883 1 The compartment forming members comprising a drug and other 2 ingredients are manufactured in one process by blending a powdered 3 drug and other core forming ingredients in a fluid bed granulator.
4 After the powdered ingredients are dry blended in the granulator, a granulating fluid, for example, polyvinyl pyrrolidone in water, is 6 sprayed onto the powdered member. The coated powder is dried in the 7 granulator. After drying a lubricant such as magnesium stearate is 8 added to the granulator. The granules are then pressed and wall 9 coated with a wall forming composition.
The dosage form of the invention can be manufactured by 11 other manufacturing techniques. For example, in one manufacture the 12 beneficial drug and other compartment core forming materials are 13 blended and pressed into a solid layer. The layer possesses 14 dimensions that corresponds to the internal dimensions of the area occupied in the dosage form. Optionally, the drug formulation can be 16 blended with a solvent, mixed by conventional methods such as 17 ballmilling, callendering, stirring, or rollmilling and then pressed 18 into a preselected shape. The compressed compartment forming mass 19 then is coated with an inner and outer wall. The wall forming composition can be applied by press coating, molding, spraying, 21 dipping or air suspension procedures. The air suspension and air 22 tumbling procedures comprise suspending and tumbling the pressed 23 composition untll surrounded with the respective walls. Dosage forms 24 comprising a drug formulation layer in contacting arrangement, and then coated with the inner and outer walls.
26 In another manufacture, the dosage form is made by the wet 27 granulation technique. In the wet granulation technique, the drug is 28 blended with other compartment forming ingredients using an organic ~2~7883 1 cosolvent, such as isopropyl alcohol-methylene dichloride, 80/20 v/v 2 (volume/volume) ~s the granulation fluid. The ingredients are passed 3 through a 40 mesh screen and blended in a mixer. Then, the blend is 4 dried for 18 to 24 hours at 42 C in a forced an oven. Next, a lubricant is added to the dry blend, and the newly formed mixture put 6 into milling jars and mixed on a jar mill for 5 to 15 minutes. The 7 composition is pressed into d layer in a Manesty~ layer press at a 8 maximum load of 2 tons. The pressed mass is fed to a Kilian~ dry cota g press and coated with an exterior wall.
DESCRIPTION OF EXAMPLES
- OF THE INVENTION
12 The following examples are merely illustrative of the 13 present invention and they should not be considered as limiting the 14 scope of the invention in anyway, as these examples and other equivalents thereof will become more apparent to those versed in the 16 dispensing art in the light of the present disclosure, the drawing 17 figures and the accompanying claims.
1g A dosage form is manufactured for delivering a beneficial drug as follows: first, a compartment-forming composition is prepared 21 by dissolving 4 9 of polyvinyl pyrrolidone in 30 ml of a cosolvent 22 consisting of 95% ethanol and 5% distilled water, and then blending 23 the moist polyvinyl pyrrolidone with a composition comprising 475 9 of 24 cimetidine hydrochloride and 10 9 of cross-linked sodium carboxymethyl cellulose previously passed through a 40 mesh stainless steel sieve to 26 yield a homogeneous blend. Next, an additional 70 ml of the cosolvent 27 consisting of ethanol and distilled water is added to the cimetidine 28 hydrochloric acid blend to form a wet granulation. The wet lZ77883 1 granulation is passed through a 10 mesh stainless steel sieve and then 2 dried at 50C for 18 to 20 hours. Then 5 9 of magnesium stearate is 3 added to the dried granulation which is passed through a 20 mesh 4 stainless steel sieve. The final blend is compressed into a number of S cores of drug having an average core weight of 742.2 mg and a hardness 6 of 12-18 kp.
7 The individual cores were coated with an inside wall-forming 8 composition comprising 30% hydroxypropylmethylcellulose phthalate, 15%
9 cellulose acetate having an acetyl content of 39.8%, 45~ sorbitol and 10% polyethylene glycol. The wall-forming coating solution consists 11 of 80/20 (v/v) acetone/water blend. The total solid content is 3%, 12 with mixing conducted with a Cole-Parmer~ stirrer. The wall forming 13 composition is coated around the cores in an air suspension machine.
14 The first applied inside wall is about 4 mils thick. Next, an outside wall about 0.5 mil thick comprising cellulose acetate having an acetyl 16 content of 32% is applied in contacting arrangement over the first 17 formed inside wall. The second form outside semipermeable wall is 18 applied using a cosolvent comprising methylene chloride/methanol, 1g 80/20, (v/v) wit~ a total solid content of 2%. The wall forming semipermeable composition is mixed with a Cole-Parmer~ mixer and 21 applied with an Aeromatic~ air suspension coater. The final dosage 22 form has a pair of spaced apart passageways of 0.38 mm diameter. The 23 dosage forms, after dispensing its drug in a distilled water 24 environment is transferred to an artificial intestinal fluid environment. In the artificial intestinal fluid, the inside wall 26 undergoes dissolution in the fluid, as the inside wall dissolves due 27 to hydroxide io~s from the artificial intestinal fluid entering the 28 dosage form, thereby causing the dosage form to collapse.
12~78a3 2 The procedure described in Example 1 is repeated with all 3 condition as previously set forth, except that in this example the 4 outside semipermeable wall consists of cellulose acetate having an acetyl content of 36~D, or cellulose acetate having an acetyl content 6 of 39.8%. The initial collapse pressure of the cellulose acetate 36%
7 wall, and the cellulose acetate 39.8% outside wall overcoated around 8 the inside wall of Example 1 is 150 mm Hg, and 150 mm Hg respectively.
g The walls exhibited a collapse pressure of 60 mm Hg, are 60 mm Hg when exposed to artificial intestinal fluid, indicating the interior wall 11 dissolves and weakens as to lose its structural-integrity and 12 continuity in the structural integrity and continuity in the presence 13 of artificial intestinal fluid exhibiting a pH greater than 4. The 14 dissolution of the wall in intestinal fluid enhances the easy of expulsion of the dosage form through the anorectal route from the 16 gastrointestinal tract.
18 A dosage form for dispensing a beneficia~ drug having an -19 acidic function is manufactured as follows: first, 600 9 of indomethacin, 2220 g-of potyethyl~ene oxide having a molecular weight 21 of 200,000 and 150 g of hydroxypropyl methyl cellulose are blended and 22 screened 40 mesh screen and then added to a mixing bowl, and dry mixed 23 for 15 to 20 minutes. Next, 2000 ml of anhydrous, denatured ethanol 24 is slowly added and mixing continued for 15 to 20 minutes more. Then, the wet mass is passed through a 16 mesh screen, spread on a white 26 paper overnight and air dried at room temperature. Next, the dry mass 27 is passed through a 16-mesh screen and 30 9 of magnesium stearate 28 added and blended therewith for 5 minutes, to yield ~he drug lZ~7883 1 containing core-forming composition.
2 Next, 4480 g of polyethylene oxide having a molecular weight 3 of about 5,000,000 is screened through a 40 mesh screen. Then, 2030 9 4 of sodium chloride, and 350 9 of hydroxypropyl methylcellulose and mixed for 15 to 20 minutes. Next, a granulating solvent consisting of 6 6 1 of ethanol absolute and 100 ml of methanol is slowly added to the 7 blending ingredients and the wet granulation mixed for 5 to 10 8 minutes. The wet granulation is removed from the mixer and then 9 passed through a 16 mesh screen onto pap-er-lined oven trays. The trays are placed into an oven at 30-35C and allowed to dry for 24 11 hours. After drying the dry granulation is passed through a 16-mesh 12 stainless steel screen and 30 9 of magnesium stearate added thereto.
13 Then, all the ingredients are blended for 15 minutes to provide a 14 uniform, homogeneous hydrophilic, hydrogel composition.
Next, a number of drug cores weighing 60 mg are pressed into 16 a layer and then placed into contacting arrangement with a 240 mg 17 1ayer of the hydrophilic, hydrogel composition~ The first and second 18 layers are surrounded with a wall forming composition 22.5% hydroxy--lg propylmethylcellulose phthalate, 25% hydroxypropylmethylcellulose, 25 polyethylene glycol, 22.5% cellulose acetate having an acetyl content 21 of 39.8% and 5% of adipic acld. The wall is applied from a cosolvent 22 comprising methylene chloride/methanol, 80/20 (v/v) with a total solid 23 content of 4%. The wall forming ingredients were mixed with a Cole-24 Parmer~ stirrer and applied with an Aeromatic~ air suspension coater.
Then, a semipermeable wall is coated around the inside wall.
26 The outside wall cellu7Ose acetate having an acetyl content of 39.8%.
27 The semipermeable wall is applied with a cosolvent comprising 28 methylene chloride/methanol, 90/10, (v/v), with a solid content of 2%
~2~7883 1 The wall forming ingredients are mixed with a Cole-Parmer~ stirrer, 2 and coated with an Aeromatic~ air suspension coater. The dosage form 3 had a 0.38 mm orifice, and after dispensing its drug layer, the inside 4 wall in artificial intestinal fluid exhibits fissuring and collapses for reducing the possible accumulation of dosage forms in the 6 gastrointestinal tract.
8 The above procedure of Example 3 is repeated with all the 9 conditions as set forth, except that in this example the outside wall comprises ethyl cellulose.
11 In summary, it will be readily appreciated that the present 12 invention contributes to the art an unobvious dosage form manufactured 13 as a drug delivery device possessing wide and practical application.
14 While the invention has been described and pointed out in detail and with reference to operative embodiments thereof, it will be understood 16 that those skilled in the art will appreciate that various changes, 17 modifications, substitutions and omissions can be made without 18 departing from the spirit of the invention. It is-intended, there-19 fore, ~hat the invention embrace those equivalents within the scope of the claims which follow.
Claims (10)
1. A dosage form for dispensing a beneficial agent formu-lation to an environment of use, the dosage form comprising:
(a) a first wall that permits the passage of fluid and comprises means for keeping its chemical integrity in a first fluid environment exhibiting a pH less than 5 and for losing its chemical integrity in a second fluid environment exhibiting a pH
greater than 5;
(b) a second wall that permits the passage of fluid and comprises means for keeping its chemical integrity in a first fluid environment exhibiting a pH less than 5 and for keeping its chemical integrity in a second environment exhibiting a pH greater than 5;
(c) a compartment formed by the first wall and the second wall with the first wall surrounding and facing the inside of the compartment and the second wall surrounding the first wall and facing the environment of use;
(d) a beneficial agent formulation in the compartment, which agent formulation forms with fluid that enters the compart-ment a fluid environment exhibiting a pH less than 5;
(e) at least one passageway through the walls for dis-pensing the beneficial agent formulation from the dosage form to the environment of use over time; and, (f) wherein fluid from the environment exhibiting a pH greater than 5 enters the dosage form causing the first wall at the end of the dispensing of the beneficial agent to lose its chemical integrity for facilitating discharge of the dosage form from the environment of use.
(a) a first wall that permits the passage of fluid and comprises means for keeping its chemical integrity in a first fluid environment exhibiting a pH less than 5 and for losing its chemical integrity in a second fluid environment exhibiting a pH
greater than 5;
(b) a second wall that permits the passage of fluid and comprises means for keeping its chemical integrity in a first fluid environment exhibiting a pH less than 5 and for keeping its chemical integrity in a second environment exhibiting a pH greater than 5;
(c) a compartment formed by the first wall and the second wall with the first wall surrounding and facing the inside of the compartment and the second wall surrounding the first wall and facing the environment of use;
(d) a beneficial agent formulation in the compartment, which agent formulation forms with fluid that enters the compart-ment a fluid environment exhibiting a pH less than 5;
(e) at least one passageway through the walls for dis-pensing the beneficial agent formulation from the dosage form to the environment of use over time; and, (f) wherein fluid from the environment exhibiting a pH greater than 5 enters the dosage form causing the first wall at the end of the dispensing of the beneficial agent to lose its chemical integrity for facilitating discharge of the dosage form from the environment of use.
2. The dosage form for dispensing the beneficial agent formulation according to claim 1, wherein the second wall contacts the first wall.
3. The dosage form for dispensing the beneficial agent formulation according to claim 1, wherein the beneficial agent is a pharmaceutically acceptable acidic drug.
4. The dosage form for dispensing the beneficial agent formulation according to claim 1, wherein the beneficial agent is a drug comprising its pharmaceutically acceptable acid addition salt.
5. The dosage form for dispensing the beneficial agent formulation according to claim 1, wherein the first wall initially is thicker than the second wall.
6. The dosage form for dispensing a beneficial agent formulation to a biological environment of use, the dosage form comprising:
(a) a first wall that permits the passage of fluid and comprises means for keeping its chemical integrity in a first fluid environment inside the dosage form exhibiting a pH less than 5 and for losing its chemical integrity in a second fluid environ-ment inside the dosage form exhibiting a pH greater than 5;
(b) a second wall that permits the passage of fluid and comprises means for keeping its chemical integrity in a first fluid environment exhibiting a pH less than 5 and for keeping its chemical integrity in a second environment exhibiting a pH greater than 5;
(c) a compartment formed by the first wall and by the second wall which first wall surrounds and faces the inside of the compartment and which second wall surrounds the first wall and faces the biological environment of use;
(d) a beneficial agent formulation in the compartment, which agent formulation forms with fluid that enters the compart-ment a fluid environment exhibiting a pH less than 5, and a hydrophilic hydrogel formulation in the compartment that aids in dispensing the agent formulation from the dosage form;
(e) at least one passageway through the walls connect-ing the compartment with the biological environment of use for dispensing the beneficial agent formulation from the dosage form over a prolonged period of time; and, (f) wherein fluid from the environment having a pH
greater than 5 enters the dosage form through the passageway causing the first wall at the end of the dispensing of the bene-ficial agent to lose its chemical integrity for facilitating discharge of the dosage form from the environment of use.
(a) a first wall that permits the passage of fluid and comprises means for keeping its chemical integrity in a first fluid environment inside the dosage form exhibiting a pH less than 5 and for losing its chemical integrity in a second fluid environ-ment inside the dosage form exhibiting a pH greater than 5;
(b) a second wall that permits the passage of fluid and comprises means for keeping its chemical integrity in a first fluid environment exhibiting a pH less than 5 and for keeping its chemical integrity in a second environment exhibiting a pH greater than 5;
(c) a compartment formed by the first wall and by the second wall which first wall surrounds and faces the inside of the compartment and which second wall surrounds the first wall and faces the biological environment of use;
(d) a beneficial agent formulation in the compartment, which agent formulation forms with fluid that enters the compart-ment a fluid environment exhibiting a pH less than 5, and a hydrophilic hydrogel formulation in the compartment that aids in dispensing the agent formulation from the dosage form;
(e) at least one passageway through the walls connect-ing the compartment with the biological environment of use for dispensing the beneficial agent formulation from the dosage form over a prolonged period of time; and, (f) wherein fluid from the environment having a pH
greater than 5 enters the dosage form through the passageway causing the first wall at the end of the dispensing of the bene-ficial agent to lose its chemical integrity for facilitating discharge of the dosage form from the environment of use.
7. The dosage form for dispensing the beneficial agent formulation according to claim 6, wherein the second wall contacts the first wall.
8. The dosage form for dispensing the beneficial agent formulation according to claim 6, wherein the beneficial agent is a pharmaceutically acceptable acidic drug.
9. The dosage form for dispensing the beneficial agent formulation according to claim 6, wherein the beneficial agent is a drug comprising its pharmaceutically acceptable acid addition salt.
10. The dosage form for dispensing the beneficial agent formulation according to claim 6, wherein the first wall initially is thicker than the second wall.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/895,551 US4743248A (en) | 1986-08-11 | 1986-08-11 | Dosage form for delivering acid sensitive beneficial agent |
| US06/895,551 | 1986-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1277883C true CA1277883C (en) | 1990-12-18 |
Family
ID=25404677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000544092A Expired - Fee Related CA1277883C (en) | 1986-08-11 | 1987-08-10 | Dosage form for delivering acid sensitive beneficial agent |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4743248A (en) |
| EP (1) | EP0257786B1 (en) |
| JP (1) | JPH075455B2 (en) |
| KR (1) | KR930008953B1 (en) |
| AU (1) | AU588202B2 (en) |
| CA (1) | CA1277883C (en) |
| DE (1) | DE3772489D1 (en) |
| ES (1) | ES2023904B3 (en) |
| NZ (1) | NZ221223A (en) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0247709B1 (en) * | 1986-04-17 | 1991-01-02 | Alza Corporation | Chlorpheniramine therapy |
| US4830860A (en) * | 1986-10-30 | 1989-05-16 | Pfizer Inc. | Stressed polymeric device for controlled release of a substance to an ambient environment |
| US5208037A (en) * | 1991-04-22 | 1993-05-04 | Alza Corporation | Dosage forms comprising polymers comprising different molecular weights |
| US5334189A (en) * | 1991-06-03 | 1994-08-02 | Wade Stephen E | Device for controlled diffusion of a chemical substance |
| US5314696A (en) * | 1991-06-27 | 1994-05-24 | Paulos Manley A | Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor |
| US5226902A (en) * | 1991-07-30 | 1993-07-13 | University Of Utah | Pulsatile drug delivery device using stimuli sensitive hydrogel |
| US5282857A (en) * | 1992-04-13 | 1994-02-01 | Perry Larry C | Gel-filled implants |
| US5523095A (en) * | 1993-12-15 | 1996-06-04 | Eastman Chemical Company | Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends |
| US5536505A (en) * | 1993-12-15 | 1996-07-16 | Eastman Chemical Company | Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends |
| US5788687A (en) * | 1994-02-01 | 1998-08-04 | Caphco, Inc | Compositions and devices for controlled release of active ingredients |
| US5554147A (en) * | 1994-02-01 | 1996-09-10 | Caphco, Inc. | Compositions and devices for controlled release of active ingredients |
| US5718700A (en) * | 1994-09-20 | 1998-02-17 | Alza Corporation | Exit means in dosage form |
| US5651979A (en) * | 1995-03-30 | 1997-07-29 | Gel Sciences, Inc. | Apparatus and method for delivering a biologically active compound into a biological environment |
| US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| PT1035834E (en) * | 1997-12-05 | 2002-09-30 | Alza Corp | OSMOTIC DOSE FORMAT COMPREHENDING FIRST AND SECOND COATINGS |
| US8524277B2 (en) * | 1998-03-06 | 2013-09-03 | Alza Corporation | Extended release dosage form |
| ATE357910T1 (en) * | 1999-11-22 | 2007-04-15 | Alza Corp | OSMOTIC DOSAGE FORM WITH TWO LAYERS |
| AR026148A1 (en) * | 2000-01-21 | 2003-01-29 | Osmotica Argentina S A | OSMOTIC DEVICE WITH PREFORMED PASSAGE THAT INCREASES SIZE |
| IT1318625B1 (en) | 2000-07-14 | 2003-08-27 | Roberto Valducci | ORAL SOLID PHARMACEUTICAL FORMULATIONS WITH MULTI-PHASE RELEASE - EMPLOYEE. |
| US7130822B1 (en) * | 2000-07-31 | 2006-10-31 | Cognos Incorporated | Budget planning |
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
| US8367111B2 (en) * | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
| US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
| WO2006021932A1 (en) | 2004-08-27 | 2006-03-02 | Koninklijke Philips Electronics, N.V. | Electronically and remotely controlled pill and system for delivering at least one medicament |
| US8747895B2 (en) * | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| US9884014B2 (en) * | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
| NZ589750A (en) | 2004-10-21 | 2012-07-27 | Aptalis Pharmatech Inc | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
| US20060105038A1 (en) * | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
| JP4600317B2 (en) | 2005-03-31 | 2010-12-15 | カシオ計算機株式会社 | Illumination device that emits at least two illumination lights having directivity and display device using the same |
| US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| CA2979355C (en) * | 2009-05-18 | 2023-02-21 | Dose Medical Corporation | Drug eluting ocular implant |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| AU2010325746B2 (en) | 2009-12-02 | 2016-02-25 | Adare Pharmaceuticals S.R.L. | Fexofenadine microcapsules and compositions containing them |
| US9668915B2 (en) * | 2010-11-24 | 2017-06-06 | Dose Medical Corporation | Drug eluting ocular implant |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
| WO2015184173A1 (en) | 2014-05-29 | 2015-12-03 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| EP3442479A1 (en) | 2016-04-20 | 2019-02-20 | Harold Alexander Heitzmann | Bioresorbable ocular drug delivery device |
| KR20200013170A (en) * | 2018-07-20 | 2020-02-06 | 주식회사 코아팜바이오 | A tablet with controlled drug release structure and a method of manufacturing the same using 3D printing technology |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU466503B2 (en) * | 1972-06-05 | 1975-10-30 | Alza Corporation | Osmotic dispenser |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
| US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| GB2108517B (en) * | 1981-06-12 | 1985-06-12 | Nat Res Dev | Hydrogels |
| US4578075A (en) * | 1982-12-20 | 1986-03-25 | Alza Corporation | Delivery system housing a plurality of delivery devices |
| US4503030A (en) * | 1983-06-06 | 1985-03-05 | Alza Corporation | Device for delivering drug to certain pH environments |
| US4627850A (en) * | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
| US4615698A (en) * | 1984-03-23 | 1986-10-07 | Alza Corporation | Total agent osmotic delivery system |
| US4624848A (en) * | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4627851A (en) * | 1984-10-26 | 1986-12-09 | Alza Corporation | Colonic-therapeutic delivery system |
| US4693895A (en) * | 1984-10-26 | 1987-09-15 | Alza Corporation | Colon delivery system |
-
1986
- 1986-08-11 US US06/895,551 patent/US4743248A/en not_active Expired - Lifetime
-
1987
- 1987-07-15 AU AU75675/87A patent/AU588202B2/en not_active Ceased
- 1987-07-21 DE DE8787306451T patent/DE3772489D1/en not_active Expired - Fee Related
- 1987-07-21 EP EP87306451A patent/EP0257786B1/en not_active Expired - Lifetime
- 1987-07-21 ES ES87306451T patent/ES2023904B3/en not_active Expired - Lifetime
- 1987-07-28 NZ NZ221223A patent/NZ221223A/en unknown
- 1987-08-10 JP JP62199671A patent/JPH075455B2/en not_active Expired - Lifetime
- 1987-08-10 CA CA000544092A patent/CA1277883C/en not_active Expired - Fee Related
- 1987-08-11 KR KR1019870008801A patent/KR930008953B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU7567587A (en) | 1988-02-18 |
| JPS6344516A (en) | 1988-02-25 |
| NZ221223A (en) | 1989-12-21 |
| KR930008953B1 (en) | 1993-09-17 |
| EP0257786A3 (en) | 1988-07-13 |
| EP0257786A2 (en) | 1988-03-02 |
| EP0257786B1 (en) | 1991-08-28 |
| DE3772489D1 (en) | 1991-10-02 |
| AU588202B2 (en) | 1989-09-07 |
| JPH075455B2 (en) | 1995-01-25 |
| US4743248A (en) | 1988-05-10 |
| ES2023904B3 (en) | 1992-02-16 |
| KR880002502A (en) | 1988-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1277883C (en) | Dosage form for delivering acid sensitive beneficial agent | |
| US4842867A (en) | Pulsed drug delivery of doxylamine | |
| US5792471A (en) | Dispensing devices powered by hydrogel | |
| US4948592A (en) | Pulsed drug delivery | |
| US4851232A (en) | Drug delivery system with means for obtaining desirable in vivo release rate pattern | |
| US4503030A (en) | Device for delivering drug to certain pH environments | |
| US4986987A (en) | Pulsed drug delivery | |
| US7108865B2 (en) | Controlled-release dosage forms of azithromycin | |
| CA2354472C (en) | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings | |
| CA1319071C (en) | Dispenser with movable matrix comprising a plurality of tiny pills | |
| US4587117A (en) | Medical device for delivering drug to pH environments greater than 3.5 | |
| US5147654A (en) | Oral osmotic device for delivering nicotine | |
| US5141752A (en) | Delayed drug delivery device | |
| NO965539L (en) | Pharmaceutical tacrine preparations | |
| JPS63297319A (en) | Administrative medicine containing movable matrix having solid characteristics | |
| GB2189995A (en) | Dosage dispenser containing osmotic solute and hydrogel | |
| JPH0428242B2 (en) | ||
| JPH05502215A (en) | Oral penetration device containing a hydrogel-driven element | |
| CA1315628C (en) | System for delivering drug with enhanced bioacceptability | |
| IE912517A1 (en) | Oral osmotic device for delivering nicotine | |
| US4747847A (en) | System for delivering potassium chloride with enhanced bioacceptability | |
| JPS6244249A (en) | Apparatus for dispensing effective drug composition to ruminant | |
| US20010038855A1 (en) | Dosage form for administering prescribed dose | |
| CA2474425A1 (en) | Osmotic delivery system | |
| US5200196A (en) | Improvement in pulsed drug therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |